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SOLID PHASE TRANSFORMATION OF CARBAMAZEPINE-SACCHARIN 
(CBZ-SAC) CO-CRYSTAL 
 
ABSTRACT 
 
A research was conducted on the solid phase transformation and stability of 
carbamazepine-saccharin co-crystal. Pharmaceutical co-crystal is one of the potential 
methods for improving the bioavailibity of drugs with low aqueous solubility. Thus, the 
purpose of this research is to determine the stable region of carbamazepine-saccharin 
(CBZ-SAC) co-crystal formation by using solution based method. In this method, three 
technique are used which are cooling crystallization, solvent evaporation and slurry, to 
prepare the chemical and use ethanol as a solvent. Different mol ratio of CBZ and SAC 
are being tested, in order to study CBZ-SAC cocrystal formation. Physical 
characterizations of the co-crystal are being characterized by differential scanning 
calorimetry and research microscope. Overall as the concentration of saccharin increase 
the melting point increase and will lead to poor solubility but mostly the melting point of 
co-crystal resulting in lower melting point. From this research can be concluded that 
CBZ-SAC co-crystal can form two forms which are plate-like and needle like. Varying 
the mol of carbamazepine and used different solvents could be used for further studies to 
see the difference trending. 
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FASA TRANSFORMASI PEPEJAL ‘CARBAMAZEPINE-SACCHARIN (CBZ-
SAC) CO-CRYSTAL’ 
 
ABSTRAK 
 
Satu penyelidikan telah dijalankan ke atas perubahan fasa pepejal dan kestabilan 
‘carbamazepine-saccharin co-crystal’. Farmasitikal ‘co-crystal’ adalah salah satu kaedah 
yang berpotensi untuk meningkatkan ‘bioavailibity’ dadah yang mempunyai kelarutan 
rendah akueus. Oleh itu, tujuan kajian ini adalah untuk menentukan julat stabil 
pembentukan ‘carnamazepine-saccharin co-crystal’ dengan menggunakan kaedah 
berasaskn larutan. Tiga teknik akan digunakan dalam kaedah ini iaitu penghabluran 
penyejukan, penyejatan pelarut dan ‘sluury’, untuk menyediakan bahan kimia dan 
menggunakan etanol sebagai pelarut. Nisbah mol CBZ dan SAC yang berlainan akan 
diuji dalam usaha untuk mengkaji pembentukan CBZ-SAC ‘co-crystal’. Pencirian fizikal 
‘co-crystal’ akan dianalisis menggunakan DSC and mikroskop penyelidikan. Apabila 
kepekatan saccharin meningkat, takat lebur akan meningkat juga dan membawa kepada   
kelarutan rendah tetapi kebanyakannya takat lebur ‘co-crystal’ adalah rendah. Daripada 
kajian ini, dapat disimpulkan bahawa CBZ-SAC co-crystal boleh membentuk dua 
bentuk iaitu ‘plate-like’ dan ‘needle-like’. Mengubah mol carbamazepine dan pelarut 
yang berbeza-beza boleh digunakan untuk kajian lanjut untuk melihat perbezaan 
trendnya. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Research Background 
 
 Drug molecules with limited aqueous solubility are currently the major problem 
for the pharmaceutical industry. These gives a lot of disadvantages such as lead to slow 
dissolution in biological fluids, insufficient and inconsistent systemic exposure and 
consequent sub-optimal efficacy in patient, particularly when delivered via the oral route 
of administration. Drug molecules can exist in the solid form in either crystalline or 
amorphous states. Because of the instability of many amorphous materials, most drugs 
are formulated in the crystalline state (Vippagunta et al., 2001).  
 Co-crystallization is a technique to modify key solid-state properties of 
pharmaceuticals which have useful attributes in terms of physical properties, such as 
solubility, hygroscopicity, stability and dissolution rate. Currently, it has been widely 
used in the pharmaceutical industry in order for improving the solubility of drugs since 
the drug often discarded during commercial production due to their low solubility.  
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A pharmaceutical co-crystal means a crystal with one of the crystal components 
as an active pharmaceutical ingredient (API) and the other called co-former. The 
Figure1.1 above shows some examples of APIs and co-former. Co-former is substances 
that are solids at ambient conditions in their pure form and in the presence of drug can 
form crystalline solids that exhibit non-ionic intermolecular interactions and contain 
both components. This can be designed by crystal engineering with the intention to 
improve the solid-state properties of an API without affecting its intrinsic structure 
(Qiao et al, 2011). 
 
Table1.1 Chemical structure of the representative APIs and co-former 
Active pharmaceutical ingredients (APIs): 
 
Co-formers: 
   
(Source: Wu et al., 2011) 
 Glutaric acid (GLU) 
Saccharin (SAC) 
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 Co-crystal can be prepared by several methods such as solvent and solid based 
methods. The solvent-based methods involve slurry conversion via solvent evaporation, 
cooling crystallization and precipitation while the solid based methods involve dry 
grinding and solvent-assisted grinding (Padrela, 2010). It can be characterized in a wide 
variety of ways. Qiao (2011) pointed out that Powder X-ray diffraction (PXRD) was the 
most commonly used method in order to characterize co-crystals. Besides that, Fourier 
transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), 
thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) were 
other common spectroscopic methods may be used. 
 
 
1.2 Problem Statement 
 
 Carbamazepine poses multiple challenges for oral drug delivery, including a 
narrow therapeutic window, autoinduction of metabolism and dissolution-limited 
bioavailability (Magali et al., 2006). Carbamazepine is characterized as having low 
solubility in an aqueous media, but a high permeability across the human intestinal 
membrane or an appropriately predictive in vitro model. Therefore, formulation 
strategies are aimed at improving the solubility, stability and dissolution rates in order to 
enhance the bioavailability of this highly permeable drug.  
 The bioavailability of oral drug substances is a function of their solubility and 
dissolution in gastric/intestinal fluids as well as the drugs ability to permeate cellular 
membranes if efficacy requires distribution away from the gastric/intestinal fluids.  
Together solubility and permeability are the basis for the biopharmaceutical 
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classification system (BCS) that segments drugs into four classifications based on these 
two properties. Solubility improvements are particularly desirable for BCS class II 
compounds that have low solubility and high permeability.  
 According to Derdour et al., (2011), pharmaceutical co-crystal emerges as a 
potential method for enhancing the bioavailability of drugs with low aqueous solubility. 
Many authors agreed with this idea.  Co-crystal are able to alter the physicochemical 
properties of active drug substances through combining drugs and additional 
components (i.e. co-formers) in the same crystal structure thereby altering solid-state 
properties and solution behavior without modifying chemical structure. 
 
 
1.3 Research Objective 
 
The objective of this experiment is to determine the stable region of 
carbamazepine-saccharin (CBZ-SAC) co-crystal formation using solution based method. 
 
 
1.4 Scope of Research 
 
 The following are the scopes of this research to support the above mentioned 
objectives: 
i) To study formation of carbamazepine-saccharin co-crystal using solution 
method via varying the mol ratio of carbamazephine and saccharin 
concentration. 
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ii) To identify the physical properties of carbamazepine-saccharin co-
crystal. 
 
 
1.5 Rationale and Significance 
 
 This study will provide a range of SAC/CBZ mol ratio for the formation of 
stabilize carbamazepine-saccharin co-crystal by using solution method. It will lead to a 
better understanding of the co-crystal formation. Co-crystal is constructed from 
intermolecular interactions such as van der Waals contact forces, Π-stacking 
interactions, and hydrogen bond (Qiao et al, 2011). Co-crystal are gaining much interest 
because the resulting new crystal forms of APIs many times have different 
pharmaceutical, physical, and chemical properties compared to the original API. 
 
 
1.6 Thesis Outline  
 
 This thesis is divided into five chapters, starting with Chapter 1. In this chapter 
will introduce the overview about co-crystal, including the problem statement, objective 
and the scope of the study also are included in this chapter.  
 Next, Chapter 2 is about literature review on co-crystal as a solid form, and 
pharmaceutical co-crystal including the molecular interaction, the formation method   
and co-crystal characterization technique. In this section, all the relevant journal, 
technical paper and books taken from those researches will be studied and discussed.  
 6 
 
 Then, Chapter 3 will be covered the parts of experimental set up and will be 
explained more details on methodology and operating procedures. The co-crystal 
formation method and characterization techniques used for this system are described in 
detail. In addition, in this chapter also explained the material used in this experiment. 
 Chapter 4 will be covered on the results and discussion of the research during the 
operation process. All the experimental result and data will be discussed in details which 
are including screening methods and characterization of co-crystal with different mol 
ratio. 
 Chapter 5 will be discussed on the conclusion can be made for the study and 
some recommendations can be taken. Figure 1.1 shows the road map of thesis. 
 
 
 
Figure 1.1 The road map of thesis 
 
INTRODUCTION  
LITERATURE 
REVIEW 
RESEARCH 
METHODOLOGY 
RESULTS AND 
DISCUSSION 
CONCLUSIONS AND 
RECOMMENDATION 
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
2.1 Co-Crystal as a Solid Form 
 
The solid forms of active pharmaceutical ingredients are important aspects of 
drug development in the pharmaceutical industry. Active pharmaceutical ingredients 
(API) can exist in a variety of distinct solid forms, including polymorphs, solvates, 
hydrates, salts, co-crystal and amorphous solids as shown in Figure 2.1. Yadav et al. 
(2009) pointed out that each form display unique physicochemical properties that can 
profoundly influence the bioavailability, manufacturability purification, stability and 
other performance characteristics of the drug. This was seen in the recent study (Qiao et 
al., 2011) that co-crystal is one of the methods of great interest for the pharmaceutical 
industry since it offer potential improvements in solubility, dissolution rate, and enhance 
other essential properties of the APIs. 
 8 
 
 
Figure 2.1 The range of single crystalline forms that is possible for an API: (a) pure 
API; (b) polymorph of pure API; (c) solvate of API; (d) clatharte hydrate/solvate of API; 
(e) salt of API; (f) pharmaceutical co-crystal. Salts and co-crystal can form hydrates, 
solvates and polymorphs. (Source: Shan et al., 2008) 
 
 
To distinguish between co-crystal and solvates are their physical state of the 
isolated pure components (BS 2009). If one component is a liquid at room temperature, 
the crystals are designated as solvates; if both are solids at room temperature; the 
crystals are designated as co-crystal.  To reduce the risk of solvate formation, solvent 
with a high solubility of the co-crystal former is chosen. 
A major limitation of salts is the APIs have to seize a suitable (basic or acid) 
ionizable site only. Co-crystal becomes an alternative to salts when APIs had limited 
pharmaceutical profiles based on their nonionizable functional group. This is because 
APIs could potentially be co-crystallized regardless of acidic, basic or ionizable groups.  
Although the solubility of the salt, which is governed by the solubility products of API 
and the counter salt, may not be much better than that of the free form, the dissolution 
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rate is usually much faster due to alterations in the microenvironmental pH (Kawakami 
2012). 
Polymorph is a crystalline solid which have the same compound or composition 
but difference crystalline form. This was seen in the recent study (Spong et al., 2004) 
that polymorphisms of carbamazepine have four forms which are the triclinic (form I), 
trigonal (form II), monoclinic (forms III and IV) and form V. Figure 2.2 shows packing 
diagram of carbamazepine polymorphs. However, the polymorphs can convert 
spontaneously from less stable to more stable forms and vice versa since the solubility is 
low. Then, Llinas and Goodman (2008) come out with suggestion which is find out the 
most stable form of polymorph instantly, so that it can be used for subsequent testing. 
 
 
Figure 2.2 Packing diagrams of carbamazepine polymorphs. From top left clockwise:  
                     I.II, III and IV (Source: Price et al., (2004) 
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Co-crystallization technology become increasingly popular through the 
development of new class of crystalline solids, called pharmaceutical co-crystal. The 
pharmaceutical co-crystal has already proven to be useful in enhancing the solubility, 
dissolution rate, stability and bioavailibity of APIs (Zhang et al., 2012).  
 
 
2.2 Pharmaceutical Co-Crystal 
 
A pharmaceutical co-crystal consists of an API (host) and a pharmaceutically 
acceptable compound (guest, co-former). Co-crystal is designed based on the principles 
of crystal engineering and supramolecular chemistry, where co-crystal components are 
selected based on favorable molecular recognition interactions.  Typically, though not 
exclusively, the drug component is hydrophobic and poorly soluble in water.  In general 
the co-formers are small organic acids, though co-formers with other ionization 
properties have been successfully co-crystallized. Table 2.1 represents some examples of 
pharmaceutical co-crystal. 
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Table 2.1 Examples of pharmaceutical co-crystal 
API Co-formers Reference  
Carbamazepine  DMSO, benzoquinone, 
terephthalaldehyde, acetone, 
saccharin, nicotinamide, acetic 
acid, formic acid, butyric acid, 
trimesic acid, 5-nitroisophtalic 
acid, adamantine-1,3,5,7-
tetracarboxylic acid, formamide 
 
(Fleischman et al., 2003) 
Indomethacin Nicotinamide, saccharin (Wu, et al. 2011) 
Fluoxetine HCl Benzoic acid, succinic acid & 
fumaric acid 
 
(Shan and Zaworotko 2008) 
Ibuprofen Nicotinamide  (Qiao et al., 2011) 
 
2.2.1 Molecular Interactions in Co-Crystal 
 
 This co-crystal is constructed from intermolecular interactions such as van der 
Waals contact forces, pi stacking interactions and hydrogen bond. Because of its 
strength and directionally, the hydrogen bond has been the most important interaction in 
molecular recognition (Spong et al., 2004). According to Etter et al., (1990), in the 
graph-set notation system that been introduced by him, four principal motif are used 
which are chains, dimers, rings and hydrogen bonds as descriptor of hydrogen molecular 
solids.  
 In addition, Dale et al., 2004, agreed and provide guidelines for the design of 
hydrogen bonded solids as follow: (i)all good proton donors and acceptors are used in 
hydrogen bonding; (ii)  if  six-member  ring  intermolecular  hydrogen bonds  can  form,  
they  will  usually  do  so  in  preference  to  forming intermolecular hydrogen bonds; 
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(iii) the best proton donors and acceptors remaining after intermolecular hydrogen-bond 
formation, form  intermolecular  hydrogen  bonds  to  one  another. Carboxylic acids, 
amides, carbohydrates, alcohols and amino acids are the examples of pharmaceutically 
acceptable co-crystal former that are able to co-crystallize with APIs as illustrated in 
Figure 2.3. 
 
 
Figure 2.3 Typical hydrogen bonds utilized in crystal engineering (Source: Qiao et
     al., 2011) 
 
 
2.3 Physiochemical Properties 
 
 The main advantage of co-crystal is the ability to generate a variety of solid 
forms of a drug that have physicochemical properties distinct from the solid co-crystal 
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components. Physiochemical properties such as crystallinity, melting point, stability, and 
dissolution rate are potentially modified by co-crystal formation. These properties can 
directly or indirectly affect the suitability of a particular API as a pharmaceutical 
product. 
 
 
2.3.1 Melting Point 
 
 The melting point of co-crystal, in general, differs from those of the individual 
components due to changes in molecular interactions, composition and structure. The 
melting point usually in between of the APIs and co-former or lower than that of the 
APIs or co-formers. For example, the melting  points  of  10  co-crystal  to  the  API  
carbamazepine  (Fleischman et al., 2003) and  their  respective  conformers  showing  
that  all  these  co-crystal  have  a  melting  point  that fell between the melting point of 
the API and their correspondent co-former.  
 
2.3.2 Stability 
 
 Stability is a very important parameter when evaluating the properties of a 
pharmaceutical co-crystal. Usually, the stability testing of a newly developed co-crystal 
includes four aspects:  relative humidity stress, thermal stress, chemical stability, and 
solution stability. For example, co-crystallization can improve the chemical stability of 
an API through rearrangement of the molecules in the crystalline lattice. 
Carbamazepine-saccharin and carbamazepine-nicotinamide co-crystal contain azepine 
